Top

International Journal of Clinical Oncology

Published in:

01-04-2020 | Computed Tomography | Original Article

Predictive value of ¹⁸F-FDG PET/CT for acute exacerbation of interstitial lung disease in patients with lung cancer and interstitial lung disease treated with chemotherapy

Authors: Kimitaka Akaike, Koichi Saruwatari, Seitaro Oda, Shinya Shiraishi, Hiroshi Takahashi, Shohei Hamada, Shinji Iyama, Yuko Horio, Yusuke Tomita, Sho Saeki, Shinichiro Okamoto, Hidenori Ichiyasu, Kazuhiko Fujii, Takuro Sakagami

Published in: International Journal of Clinical Oncology | Issue 4/2020

Abstract

Background

We examined whether fluorine-18 2-fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography (¹⁸F-FDG PET/CT) performed before chemotherapy could predict the onset of acute exacerbation of interstitial lung disease (AE-ILD) in patients with lung cancer and ILD treated with chemotherapy.

Methods

Thirty-three patients with lung cancer and ILD who underwent ¹⁸F-FDG PET/CT and were treated with chemotherapy at Kumamoto University Hospital between April 2006 and March 2018 were retrospectively analyzed. The maximum standardized uptake value (SUV_max) of interstitial lesions was measured to quantify the background ILD activity. A prediction model of AE-ILD was developed using logistic regression analyses for the SUV_max, and receiver operating characteristic (ROC) curve analyses were conducted.

Results

Among the 33 patients, 7 experienced AE-ILD. The SUV_max of contralateral interstitial lesions was significantly higher in patients with vs. without AE-ILD (median SUV_max: 2.220 vs. 1.795, P = 0.025). Univariable logistic regression analyses showed that the SUV_max of contralateral interstitial lesions trended towards being significantly associated with the onset of AE-ILD [odds ratio: 8.683, 95% confidence interval (CI) 0.88–85.83, P = 0.064]. The area under the ROC curve of the SUV_max for predicting AE-ILD was 0.780 (95% CI 0.579–0.982, P = 0.025). The optimal cut-off value for SUV_max was 2.005, with sensitivity and specificity values of 0.857 and 0.769, respectively.

Conclusions

The SUV_max of contralateral interstitial lesions in ¹⁸F-FDG PET/CT images might be useful for predicting the onset of AE-ILD in patients with lung cancer and ILD treated with chemotherapy.

Available only for authorised users

Ozawa Y, Suda T, Naito T et al (2009) Cumulative incidence of and predictive factors for lung cancer in IPF. Respirology (Carlton, Vic) 14(5):723–728. https://doi.org/10.1111/j.1440-1843.2009.01547.x CrossRef

Tomassetti S, Gurioli C, Ryu JH et al (2015) The impact of lung cancer on survival of idiopathic pulmonary fibrosis. Chest 147(1):157–164. https://doi.org/10.1378/chest.14-0359 CrossRefPubMed

Minegishi Y, Takenaka K, Mizutani H et al (2009) Exacerbation of idiopathic interstitial pneumonias associated with lung cancer therapy. Intern Med (Tokyo, Japan) 48(9):665–672CrossRef

Shukuya T, Ishiwata T, Hara M et al (2010) Carboplatin plus weekly paclitaxel treatment in non-small cell lung cancer patients with interstitial lung disease. Anticancer Res 30(10):4357–4361PubMed

Kenmotsu H, Naito T, Kimura M et al (2011) The risk of cytotoxic chemotherapy-related exacerbation of interstitial lung disease with lung cancer. J Thorac Oncol 6(7):1242–1246. https://doi.org/10.1097/JTO.0b013e318216ee6b CrossRefPubMed

Kakiuchi S, Hanibuchi M, Tezuka T et al (2017) Analysis of acute exacerbation of interstitial lung disease associated with chemotherapy in patients with lung cancer: a feasibility of S-1. Respir Investig 55(2):145–152. https://doi.org/10.1016/j.resinv.2016.10.008 CrossRefPubMed

Enomoto Y, Inui N, Kato T et al (2016) Low forced vital capacity predicts cytotoxic chemotherapy-associated acute exacerbation of interstitial lung disease in patients with lung cancer. Lung Cancer (Amsterdam, Netherlands) 96:63–67. https://doi.org/10.1016/j.lungcan.2016.03.017 CrossRef

Chao F, Zhang H (2012) PET/CT in the staging of the non-small-cell lung cancer. J Biomed Biotechnol 2012:783739. https://doi.org/10.1155/2012/783739 CrossRefPubMedPubMedCentral

Justet A, Laurent-Bellue A, Thabut G et al (2017) [(18)F]FDG PET/CT predicts progression-free survival in patients with idiopathic pulmonary fibrosis. Respir Res 18(1):74. https://doi.org/10.1186/s12931-017-0556-3 CrossRefPubMedPubMedCentral

10.

Raghu G, Remy-Jardin M, Myers JL et al (2018) Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med 198(5):e44–e68. https://doi.org/10.1164/rccm.201807-1255ST CrossRef

11.

Raghu G, Collard HR, Egan JJ et al (2011) An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 183(6):788–824. https://doi.org/10.1164/rccm.2009-040GL CrossRefPubMedPubMedCentral

12.

Groves AM, Win T, Screaton NJ et al (2009) Idiopathic pulmonary fibrosis and diffuse parenchymal lung disease: implications from initial experience with 18F-FDG PET/CT. J Nucl Med 50(4):538–545. https://doi.org/10.2967/jnumed.108.057901 CrossRefPubMed

13.

Brown RS, Leung JY, Kison PV et al (1999) Glucose transporters and FDG uptake in untreated primary human non-small cell lung cancer. J Nucl Med 40(4):556–565PubMed

14.

van Baardwijk A, Dooms C, van Suylen RJ et al (2007) The maximum uptake of (18)F-deoxyglucose on positron emission tomography scan correlates with survival, hypoxia inducible factor-1alpha and GLUT-1 in non-small cell lung cancer. Eur J Cancer (Oxford, England 1990) 43(9):1392–1398. https://doi.org/10.1016/j.ejca.2007.03.027 CrossRef

15.

El-Chemaly S, Malide D, Yao J et al (2013) Glucose transporter-1 distribution in fibrotic lung disease: association with [(1)(8)F]-2-fluoro-2-deoxyglucose-PET scan uptake, inflammation, and neovascularization. Chest 143(6):1685–1691. https://doi.org/10.1378/chest.12-1359 CrossRefPubMed

16.

Andrianifahanana M, Hernandez DM, Yin X et al (2016) Profibrotic up-regulation of glucose transporter 1 by TGF-beta involves activation of MEK and mammalian target of rapamycin complex 2 pathways. FASEB J 30(11):3733–3744. https://doi.org/10.1096/fj.201600428R CrossRefPubMedPubMedCentral

17.

Bergeron A, Soler P, Kambouchner M et al (2003) Cytokine profiles in idiopathic pulmonary fibrosis suggest an important role for TGF-beta and IL-10. Eur Respir J 22(1):69–76CrossRef

18.

Lodge MA (2017) Repeatability of SUV in Oncologic (18)F-FDG PET. J Nucl Med 58(4):523–532. https://doi.org/10.2967/jnumed.116.186353 CrossRefPubMedPubMedCentral

Title: Predictive value of 18F-FDG PET/CT for acute exacerbation of interstitial lung disease in patients with lung cancer and interstitial lung disease treated with chemotherapy
Authors: Kimitaka Akaike
Koichi Saruwatari
Seitaro Oda
Shinya Shiraishi
Hiroshi Takahashi
Shohei Hamada
Shinji Iyama
Yuko Horio
Yusuke Tomita
Sho Saeki
Shinichiro Okamoto
Hidenori Ichiyasu
Kazuhiko Fujii
Takuro Sakagami
Publication date: 01-04-2020
Publisher: Springer Singapore
Keywords: Computed Tomography
Lung Cancer
Computed Tomography
Lung Cancer
Positron Emission Tomography
Lung Cancer
Cytostatic Therapy
Published in: International Journal of Clinical Oncology / Issue 4/2020
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-019-01584-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 4/2020

Research on the predicting power of the revised Tokuhashi system: how much time can surgery give to patients with short life expectancy?

Changing pattern of tumor markers in recurrent colorectal cancer patients before surgery to recurrence: serum p53 antibodies, CA19-9 and CEA

Efficacy of modified FOLFOX6 chemotherapy for patients with unresectable pseudomyxoma peritonei

The impact of postoperative inflammation on recurrence in patients with colorectal cancer

Comparable efficacy and safety between second-line and later-line nivolumab therapy for metastatic renal cell carcinoma

Preoperative lymphocyte-to-monocyte ratio predicts postoperative infectious complications after laparoscopic colorectal cancer surgery

Keynote webinar | Spotlight on antibody–drug conjugates in cancer